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Abstract
Stage I lung cancer has a high cure rate with surgery, although many patients are not surgical
candidates due to comorbid conditions. Historically, non-operative treatment has been disappointing.
New and promising ablative therapies offer a curative option.
Introduction and context
The standard of care for stage I non-small cell lung cancer
(NSCLC) according to the National Comprehensive
Cancer Network Guidelines is lobectomy with lymph
node dissection [1]. Radiation is standard treatment for
patients who cannot tolerate surgery. Ablative therapy
with stereotactic body radiation therapy (SBRT) offers
high local control (LC) with limited morbidity. Percuta-
neous radiofrequency ablation (RFA) is being explored as
another option for treating medically inoperable patients.
This is a review of ablative non-surgical management of
stage I NSCLC.
Recent advances
Stereotactic body radiation therapy
Historically, radiation for early-stage lung cancer has
resulted in low rates of LC. Improvements in set-up
reproducibility, tumor localization, and compensation
for respiratory motion have facilitated the development
of SBRT. SBRT uses highly conformal, high-dose, ablative
radiation delivered in one to five fractions. Treatment is
delivered with multiple fields, limiting the dose to
normal tissues while delivering an ablative tumor dose.
Several institutions have reported safe and effective
treatment with SBRT since the first results were published
in 1995 [2]. LC rates with SBRT are 80-95% (Table 1).
Differences in LC rates are partially explained by different
total dose, fractionation schedules, and tumor size. An
accepted method of normalizing the radiation dose is the
biologically equivalent dose (BED) calculation that
accounts for total dose, dose per fraction, and elapsed
timefortreatmentdelivery.Areviewof257patientstreated
with stage I NSCLC reported significantly lower local
recurrencerateswithBEDofatleast100Gycomparedwith
BED of less than 100 Gy (8.4% versus 42.9%) [3]. Nguyen
et al. [4] published an excellent review of the literature of
SBRToutcomesbasedonBEDcalculations.Treatmentwith
BED of at least100 Gy in14 publishedseries resulted in LC
of 74-100% compared with 57-91% with BED of less than
100 Gy in 10 published series [4].
Indiana University (Bloomington, IN, USA) conducted a
phase I dose escalation study for medically inoperable
lung cancer [5]. The maximal tolerated dose was not
reachedfor T1/2tumorsofless than5cmdespitereaching
60-66 Gy in three fractions. They subsequently completed
a phase II trial with 60 Gy in three fractions for T1 and T2
tumorsoflessthan5cm.Theactuarial2-yearLCwas95%,
and isolated hilar or mediastinal nodal relapse was rare
[6]. Grade 5 toxicity (toxicity resulting in death) was
reportedinpatientswithcentrallylocatedtumors.Thisled
to a definition of a ‘central zone’ inside of which the
radiation dose must be adjusted to prevent unacceptable
toxicity [6]. Grade 5 toxicity is effectively avoided with
appropriate patient selection and dose modification for
central lesions [7-9]. A multicenter phase I/II dose
escalation study for centrally located lung tumors is
underway.Thestartingdoseis50Gyat10Gyperfraction.
The phase II data of Timmerman and colleagues [6] were
the basis for a multicenter cooperative group phase II
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F1000 Medicine Reportsstudy presented in 2009 that used 60 Gy in three
fractions to treat peripherally located tumors [7]. There
was no grade 5 toxicity. Grade 3 and grade 4 adverse
e v e n t sw e r er e p o r t e di n2 4 %a n d4 %o fp a t i e n t s ,
respectively. The most common severe adverse events
were pulmonary/upper respiratory and musculoskeletal.
LC was 93.7% and there were no regional failures [7].
Musculoskeletal complications consist of rib fractures
and soft tissue fibrosis. The rate of this complication is
low in individual studies but is regularly reported.
Improved understanding of chest wall and soft tissue
tolerances with hypofractionated treatments minimizes
chest wall toxicity [10,11].
Current areas of investigation include evaluation of
single-fraction SBRT for inoperable patients. These
schedules have been shown to have an efficacy similar
to that of 60 Gy in three fractions, may result in less
toxicity, and offer a more convenient schedule [12,13].
SBRT in operable patients is being studied in a multi-
center cooperative group trial with the primary objective
of determining whether SBRT achieves acceptable LC in
operable patients. All patients are treated with SBRT and
are resected with evidence of progression.
Radiofrequency ablation
Percutaneous image-guided RFA is used to treat solid
tumors by inducing controlled coagulation necrosis [14].
This procedure is acceptedas a viable option for treatment
of hepatic lesions and recently has been proposed as an
option to treat inoperable lung tumors, although the US
Food and Drug Administration has not cleared any RFA
devices for the specific treatment indication of partial or
complete ablation of lung tumors. As with other new
procedures, patients should be treated in clinical studies.
Lesions generally considered eligible for RFA are at least
1 cm from the trachea, main bronchi, aorta, and the
pulmonary artery and its major branches. Lesions near
the diaphragm, lung apex, and scapula are locations that
might be technically difficult to access for RFA.
The efficacy of RFA for NSCLC is difficult to assess as the
majority of series include primary and secondary tumors.
Additionally, there are few reported prospective studies
(Table 2).
The RAPTURE study, a prospective multicenter clinical
trial aimed at assessing feasibility, safety, and effectiveness
of lung malignancies, has been reported [14]. This study
included primary and metastatic lung tumors of 3.5 cm or
less. Sustained LC at 1 year was seen in 88% of 85
assessable patients out of a total of 105 patients under-
going therapy. There were no treatment-related deaths.
Pneumothorax developed in 27 of the 137 procedures,
and pleural effusion requiring drainage developed in 4
patients.
Studies have reported improved control for smaller
tumors. Simon and colleagues [15] reported a single-
institution retrospective review of 153 consecutive
patients with 183 inoperable lesions treated with RFA
for metastatic and primary lung tumors. The 1-, 2-, 3-, 4-,
and 5-year local tumor progression-free rates, respectively,
were 83%, 64%, 57%, 47%, and 47% for tumors of 3 cm
or smaller and 45%, 25%, 25%, 25%, and 25% for
tumors larger than 3 cm. The overall pneumothorax rate
was 28.4%, with a 9.8% chest tube insertion rate. The
overall 30-day procedure-specific mortality rate was 2.6%.
Toxicity is generally reported as acceptable, although the
reportedtoxicity variesbetween series. Zhu andcolleagues
Table 1. Stereotactic body radiation therapy
Study Radiation Tumor size Local control Overall survival
Nagata et al. [12], 2005 12 Gy × 4 <4 cm 94% (3 years) 72% (T1); 71% (T2) (1 year)
83% (T1); 72% (T2) (3 years)
Timmerman et al. [6], 2006 20-22 Gy × 3 ≤7 cm 95% (2+ years) 55% (2 years)
Hara et al. [13], 2006 30-34 Gy × 1 <4 cm 80% (3 years) 75% (1 year)
41% (2 years)
Onishi et al. [3], 2007 Variable 7-58 mm (median 28) BED >100, 84.2%; BED >100; 5 years
BED <100, 36.5% (3 years) 54% (medically inoperable)
75% (operable, refused surgery)
Hof et al. [17], 2007 19-30 Gy × 1 ≥5 cm 68% (3 years), 100% local control




Lagerwaard et al. [8], 2008 7.5-20 Gy × 3-8 T1-2 93% (2 years) 81% (1 year)
64% (2 years)
Baumann et al. [18], 2008 15 Gy × 3 T1-2 93% (2 years) T1: 100% (2 years) 52% (3 years)
Timmerman et al. [7], 2009 20 Gy × 3 ≤5 cm 93.7% 72% (2 years)
Bradley et al. [9], 2005 18 Gy × 3 or 9 Gy × 5 1-5 cm (median 2 cm) 86% (2 years); no failures with
maximum dose ≥67 Gy
BED, biologically equivalent dose.
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treatment for lung tumors. The overall procedure-related
morbidity was 15.2-55.6%, and mortality was 0-5.6%.
The most common reported toxicity was pneumothorax,
with the majority being self-limited. Chest tube was
required in 3.3-38.9%. More prospective data are needed
to define the role of RFA and proper patient selection in
order to minimize procedure toxicity.
Implications for clinical practice
Historically, treatment for medically inoperable early-
stage NSCLC was limited to palliation. Currently, SBRT
results in excellent LC rates and acceptable toxicity and
therefore presents a curative option for patients with
medically inoperable NSCLC. SBRT has been system-
atically studied for primary lung tumors in several
studies, including a prospective multi-institution study
with strict quality standards. According to early data, RFA
for the treatment of lung tumors has been shown to be
effective. Additional prospective data are necessary.
Abbreviations
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